Gain Therapeutics, Inc. (GANX)
Automate Your Wheel Strategy on GANX
With Tiblio's Option Bot, you can configure your own wheel strategy including GANX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol GANX
- Rev/Share 0.0
- Book/Share 0.2015
- PB 8.3877
- Debt/Equity 0.031
- CurrentRatio 2.2177
- ROIC -3.0566
- MktCap 50608064.0
- FreeCF/Share -0.6669
- PFCF -2.6453
- PE -2.3165
- Debt/Assets 0.0154
- DivYield 0
- ROE -2.4756
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | GANX | Scotiabank | -- | Sector Outperform | -- | $12 | March 7, 2025 |
| Initiation | GANX | ROTH MKM | -- | Buy | -- | $7 | Dec. 6, 2024 |
News
Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
GT-02287 protects dopaminergic neurons against mitochondrial toxin MPP+ suggesting an action on mitochondrial GCase in addition to its improvement of lysosomal GCase activity GT-02287 protects dopaminergic neurons against mitochondrial toxin MPP+ suggesting an action on mitochondrial GCase in addition to its improvement of lysosomal GCase activity
Read More
Gain Therapeutics to Participate at The Citizens Life Sciences Conference
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
BETHESDA, Md., May 01, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President and CEO of Gain, will present and participate in one-on-one meetings at The Citizens Life Sciences Conference, being held May 7th-8th in New York City, NY.
Read More
Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders
Published: April 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
BETHESDA, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced an oral poster presentation at the International Association of Parkinsonism and Related Disorders (IAPRD) 30th World Congress on Parkinson's Disease and Related Disorders, being held May 7th-10th in New York City, NY.
Read More
Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update
Published: March 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
First Analysis from Phase 1b Study of GT-02287 in Parkinson's Disease Expected in Q2 2025 First Analysis from Phase 1b Study of GT-02287 in Parkinson's Disease Expected in Q2 2025
Read More
About Gain Therapeutics, Inc. (GANX)
- IPO Date 2021-03-19
- Website https://www.gaintherapeutics.com
- Industry Biotechnology
- CEO Mr. Gene Mack M.B.A.
- Employees 23